FY2025 EPS Estimates for Aldeyra Therapeutics, Inc Reduced by Analyst (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Investment analysts at Leerink Partnrs dropped their FY2025 EPS estimates for shares of Aldeyra Therapeutics in a research note issued to investors on Tuesday, July 9th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will earn $0.50 per share for the year, down from their previous estimate of $0.55. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.23) per share.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06).

A number of other equities analysts have also weighed in on ALDX. StockNews.com lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Oppenheimer restated an “outperform” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Monday, May 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research report on Monday, May 6th.

Aldeyra Therapeutics Stock Performance

Shares of Aldeyra Therapeutics stock opened at $3.86 on Thursday. Aldeyra Therapeutics has a fifty-two week low of $1.42 and a fifty-two week high of $8.38. The company has a market capitalization of $229.32 million, a P/E ratio of -7.57 and a beta of 1.45. The company has a fifty day moving average of $3.72 and a 200 day moving average of $3.59.

Institutional Investors Weigh In On Aldeyra Therapeutics

Hedge funds have recently made changes to their positions in the company. Kennedy Capital Management LLC lifted its position in Aldeyra Therapeutics by 3.3% during the first quarter. Kennedy Capital Management LLC now owns 1,318,155 shares of the biotechnology company’s stock valued at $4,310,000 after purchasing an additional 42,009 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 106.3% in the 1st quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock valued at $1,478,000 after acquiring an additional 233,169 shares during the last quarter. Los Angeles Capital Management LLC grew its position in Aldeyra Therapeutics by 240.9% in the first quarter. Los Angeles Capital Management LLC now owns 380,773 shares of the biotechnology company’s stock worth $1,245,000 after acquiring an additional 269,061 shares in the last quarter. International Assets Investment Management LLC increased its stake in Aldeyra Therapeutics by 319.2% during the fourth quarter. International Assets Investment Management LLC now owns 205,335 shares of the biotechnology company’s stock worth $7,210,000 after acquiring an additional 156,353 shares during the last quarter. Finally, Woodstock Corp raised its position in Aldeyra Therapeutics by 5.9% during the second quarter. Woodstock Corp now owns 180,806 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 10,091 shares during the period. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.